Keywords
How to Cite
Abstract
Luspatercept acts as a “ligand trap” to neutralize negative regulators in late erythropoiesis. It was approved by the US Food and Drug Administration and the European Medicines Agency (EMA) in 2020 for the treatment of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts and myelodysplastic/myeloproliferative neoplasms with ring
sideroblasts and thrombocytosis requiring red blood cell transfusion. It is positioned as a second line treatment after erythropoiesis-stimulating agents failure or for patients with high serum erythropoietin levels.
References
Greenberg PL, Tuechler H, Schanz J, y col. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120 (12): 2454-2465.
Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion 2012; 52(10):2131-2138.
Cheson BD, Greenberg PL, Bennett JM y col. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
Platzbecker U,Fenaux P, Adès L y col. Proposals for revised IWG2018 hematological response criteria in patients with MDS included in clinical trials. Blood 2019;133(10):1020-1030.
Penaux P, Platzbecker U, Adès L. How we manage adults with myelodysplastic syndrome. Br. J Haematology 2020;189(6) 1016-1027.
Kubasch AS, Fenaux P, and Platzbecker U. Development of luspatercept to treat ineffective erythropoiesis. Blood 2021; (5):1565-1575.
Komrokji RS. Luspatercept in Myelodysplastic Syndromes: Who and When? Hematol Oncol Clin North Am 2020; 34(2):393-400
Valent P, Büsche G, Theurl I y col. Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica 2018;103(10):1593–603.
Fenaux P, Kiladjian JJ and Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood 2019; 133:790-794.
Verma A, Suragani RNVS, Aluri S, et al. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. J Clin Invest. 2020; 130(2):582-589.
Markham A. Luspatercept: First Approval. Drugs 2020; 80:85-90
Celgene Corporation. Highlights of prescribing information for REBLOZYL (luspatercept-aamt). Revised November 2019. https://www.accessdata.fda. gov/drugsatfda_docs/label/2019/761136lbl.pdf. November 2020.
Kenneth M. A, Mark J. Allison, McClure T. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. American Journal of Hematology 2014,89:766-770
Platzbecker U,Germing U,Götze KS y col. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes. (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338-1347.
Fenaux P, Platzbecker U, Mufti GJ y col. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140-151.
Zeidan AM, Platzbecker U, García-Manero G y col. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. To the editor. Blood, Agosto 2022.
Cappellini MD, Viprakasit V, Taher AT y col. BELIEVE Investigators. A phase 3 trial of luspatercept in patients with transfusion-dependent b-thalassemia. N Engl J Med. 2020;382(13):1219-1231.
Komrokji RS, Platzbecker U, Fenaux P. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis Leukemia, 2022;36:1432–1435.
Fenaux P, Santini V, Komrokji RS y col. Long term utilization and benefit of luspatercept in patients with lower-risk myelodysplastic syndromes from MEDALIST trial. HemaSphere, 2022;6:(S3).
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar